Fig. 9.

EGFR TKI treatment in combination with β-catenin inhibition strongly attenuates tumor onset in EGFR mutant NSCLC in vivo. a Human HCC4006 subcutaneous xenografts treated with erlotinib (50 mg/kg/day) or ICG-001 (150 mg/kg/day) alone or in combination for 5 days in a week for 9 weeks. b Overall survival analysis of HCC4006 xenograft mice that were treated with erlotinib or ICG-001 alone or in combination (P = 0.0001). c Human HCC827 subcutaneous xenografts were grown in mice that were treated with erlotinib (50 mg/kg/day) alone or in combination with ICG-001 (150 mg/kg/day) for 5 days a week for 3 weeks. After treatments were stopped, tumor recurrence was compared between the two groups. d Overall survival analysis of HCC827 xenograft mice that were treated with erlotinib alone or in combination with ICG-001 (P = 0.0001) for 21 days. Overall survival was determined after treatments were stopped. For (a) error bars represent SEM